Rockville, Md. (September 26, 2023) – Cellphire Therapeutics, Inc., a clinical stage biotechnology company developing next-generation allogeneic cellular therapeutics, today announced the United States Patent and Trademark Office (USPTO) issued a patent, entitled Platelets as Delivery Agents (US Patent 11,767,511, B2 ('511 Patent) covering innovation in the use of Freeze-Dried Platelet-Derived Hemostat Technology (FPH) for select drug delivery applications. FPH, also known as Thrombosomes®, creates a novel, shelf-stable hemostatic agent currently in Phase II clinical trials.
"This patent expands upon our core hemostatic cell preservation technology and is the first issued innovation for our drug delivery portfolio. The issuance of the ‘511 patent provides protection through 2042 and further demonstrates Cellphire Therapeutics’ emphasis on innovation and our ability to develop unique intellectual property. The use of stabilized platelets as targeted drug delivery vehicles has broad medical applications including oncology, cardiovascular disease, immunology, and many others” said Keith Moskowitz, VP of Discovery, and Research.
"This is an important milestone for the company toward protecting the company’s innovations and investments related to our longer-term portfolio. Drug delivery with platelets represents a future platform technology for us,” said Mike Gaffney, Cellphire Therapeutics CEO. “This is in keeping with our vision of saving lives with our cellular therapeutics.”
About Cellphire Therapeutics
Cellphire Therapeutics, Inc. is a biotechnology company developing next-generation allogeneic cellular therapeutics. The company is applying its proprietary cell stabilization technology first to platelets, to develop lifesaving products. Its lead investigational product is Thrombosomes®, a freeze-dried hemostatic derived from human platelets. Cellphire’s technologies support a wide range of potential medical applications for Orphan populations to surgical, trauma, traumatic brain injury (TBI) and intercranial hemorrhage (ICH) unmet clinical needs, among other things. For more information, visit www.cellphire.com.
Vice President, Business Operations